Key result
A systematic literature screen was conducted to identify molecules that modulate Cav2.3 voltage-gated Ca2+ channels to expand the availability of pharmacologic modulators beyond SNX-482.
Systematic Review
This systematic review aims to identify pharmacologic modulators of the Cav2.3 voltage-gated calcium channel to facilitate future investigations of its physiological and pathophysiological roles.
Membrane-bound voltage-gated Ca2+ channels (VGCCs) are targets for specific signaling complexes, which regulate important processes like gene expression, neurotransmitter release and neuronal excitability. It is becoming increasingly evident that the so called "resistant" (R-type) VGCC Cav2.3 is critical in several physiologic and pathophysiologic processes in the central nervous system, vascular system and in endocrine systems. However its eponymous attribute of pharmacologic inertness initially made in depth investigation of the channel difficult. Although the identification of SNX-482 as a fairly specific inhibitor of Cav2.3 in the nanomolar range has enabled insights into the channels properties, availability of other pharmacologic modulators of Cav2.3 with different chemical, physical and biological properties are of great importance for future investigations. Therefore the literature was screened systematically for molecules that modulate Cav2.3 VGCCs.
No takes yet. Share an insight, caveat, or question.
Schneider et al. (2013) conducted a systematic review in Cav2.3 VGCC modulation. Pharmacologic modulators of Cav2.3 was evaluated. A systematic literature screen was conducted to identify molecules that modulate Cav2.3 voltage-gated Ca2+ channels to expand the availability of pharmacologic modulators beyond SNX-482.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: